Pasithea Therapeutics -CW26KTTAWPreferred / convertible
13F holders, Q3 2024 (September 30)5holders −1
1new positions
2sold out
$0.04avg. 13F price*
At the end of Q3 2024, 5 institutions reported holding Pasithea Therapeutics -CW26 (KTTAW) in their 13F filings, down 1 from Q2 2024. 1 opened new positions and 2 sold out. The largest holders were Kepos Capital LP ($12K), Warberg Asset Management LLC ($9K) and Armistice Capital, LLC ($2K).
- Company
- Pasithea Therapeutics -CW26
- CUSIP
- 70261F111
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $3 |
| Exits | 2 | $144 |
All 13F filers, Q2 2024 → Q3 2024: 100 shares bought and 28,906 shares sold, net −28,806 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Kepos Capital LP | — | No change | 334,600 | $12K |
| Warberg Asset Management LLC | — | Reduce -5.6% | 263,001 | $9K |
| Armistice Capital, LLC | — | No change | 50,000 | $2K |
| Marex Group Ltd | — | No change | 25,000 | $873 |
| Clear Street LLC | — | New | 100 | $3 |
"% of holder's portfolio" is KTTAW's weight in each manager's 13F, not the share of Pasithea Therapeutics -CW26 the manager owns.